Sequential, a leader in genomic testing from non-invasive human clinical samples, today announced the successful close of its first equity round, securing $3.5 million. The round was co-led by ...
Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results